Vividion Therapeutics, Inc.

November is #LungCancerAwarenessMonth, a time to recognize and raise awareness of lung cancer, the leading cause of cancer deaths in the U.S. There is a critical need to improve treatment for this devastating disease that typically has a poor prognosis. At Vividion we are dedicated to addressing this substantial unmet need by developing novel treatments to important targets with no existing therapeutics. Our team is targeting both the KEAP1-NRF2 and STAT3 pathways in new ways. These pathways play essential roles in the growth and resistance of many solid tumors, including non-small cell lung cancer (#NSCLC), which accounts for most of all lung cancer cases. Our lead candidates VVD-037 and VVD-850, which we are currently evaluating in Phase 1 clinical trials, hold the potential to dramatically shift the treatment paradigm for NRF2- and STAT 3-activated cancers, including lung cancer. #TeamVividion #CancerResearch

On #NationalSTEMDay, we celebrate #TeamVividion who uses STEM each day to pioneer drug discovery and development as well as the next generation of STEM leaders.?We need people with science, technology, engineering and math (#STEM) skills to solve some of the world’s toughest problems.?Take a moment to review and share the many resources available, which can inspire students and early career individuals to pursue a career in STEM, a field that drives crucial innovation and progress. ? Explore STEM resources with Institute of Education Sciences:?https://bit.ly/48LQCbd ? Celebrate National STEM Day with free activities from Create & Learn: https://bit.ly/4hIapfE

We’re thrilled to announce we have a new look and website! This new brand showcases our innovative chemoproteomics platform, growing clinical-stage pipeline, and the tremendous team that makes all of our accomplishments possible. We encourage you to visit the site to learn more about our commitment to transforming drug discovery and patients’ lives by targeting currently undrugged disease-causing proteins.? ?? Join us in celebrating this new chapter of our work in leading the small molecule revolution. Visit our new website at: https://vividion.com/ ?? #TeamVividion #Oncology #CancerResearch #Biotechnology #science #Immunology #Immunologyresearch

It’s #NationalChemistryWeek! ? At Vividion, we recognize the essential role that chemistry plays in our everyday lives and its transformative impact on our scientific endeavors, driving advancements that shape the future of medicine. We celebrate the groundbreaking work of our talented chemists – their passion for discovery propels innovation in developing selective small molecules for cancer and immune disorders. ? We asked some of our chemistry-focused team members to share their perspectives on the importance of chemistry and just how deeply it is engrained in our daily lives, both in the lab and beyond. ? #DrugDevelopment #TeamVividion

In our latest installment of “Behind the Science,” Vividion CEO, Aleksandra Rizo talks with Matt Patricelli, Vividion’s first employee and now CSO, about some of the lessons he has learned in his eight years at Vividion. Discover more about his upcoming presentations at the British Pharmacological Society and Stanford Cancer Institute, where he’ll discuss Vividion’s successes in drugging challenging targets using chemoproteomics screening, along with the concept of “complex pharmacology.”? ? #TeamVividion?

Activation of the transcription factor NRF2 is correlated with certain types of aggressive, treatment-resistant cancers and poor patient outcomes. Transcription factors, however, are notoriously challenging to drug, and to date, no direct NRF2 antagonistic therapies exist. Using our unique covalent-first #chemoproteomics screening approach, we have identified a first-in-class NRF2 inhibitor that acts by a new mechanism to regulate this transcriptional circuit and dramatically degrade NRF2. Learn more about this work that is supporting our ongoing Phase 1 clinical trial, which has the potential to dramatically shift the treatment paradigm of NRF2-activated cancers. #CancerResearch #Biotechnology #teamVividion

This week at the RAS-Targeted Drug Development Summit, Joseph Klebba, Associate Director Oncology Early Discovery Sciences, will present on small molecules Vividion has optimized to disrupt the PI3Kα/AKT pathway that is critical to RAS-activated cancers. These small molecules specifically disrupt the RAS-PI3Kα interaction, blocking this key signaling cascade while avoiding the toxicities typically encountered with direct lipid kinase inhibitors. Join us for our latest pre-clinical data, including patient-derived xenografts.

Despite progress in understanding cancer drivers and how to intervene, 90% of disease-causing proteins remain undrugged. Closing this gap is a critical unmet need for patients that we are addressing every day at Vividion.??? ? This #WorldCancerResearchDay, we’re highlighting our commitment to improving the lives of patients by pioneering new methods to target hard-to-reach disease targets and developing novel treatments that shape the future of cancer care.?? ? Join us in honoring all the groundbreaking researchers who are working tirelessly to make a difference. ? #CancerResearch #Biotechnology??

We are excited to launch our new “Behind the Science” series featuring one-on-one conversations with the people driving Vividion’s culture of innovation. This series will showcase our team’s pioneering work, shed light on cutting-edge research, and provide a behind-the-scenes look at our company and the scientific approach that powers it. ? In our first article, we’re thrilled to feature Vivdion CEO Aleksandra Rizo's conversation with David Weinstein, VP of Chemistry. Read more to learn about his upcoming presentation at the American Chemical Society’s Fall 2024 meeting, where he’ll unveil the first small molecule activator of Kelch-like ECH associated protein 1 (KEAP1).

What a beautiful day to celebrate the dreams and aspirations of the future stars of biotech! We were delighted to join with Life Science Cares San Diego to host an afternoon of lively conversation and career networking for the 2024 Project Onramp cohort.? ? Project Onramp connects motivated college students from diverse backgrounds to paid internships hosted at life science companies, where they gain exposure to opportunities in the field, cultivate a network of peers, and acquire important career and life skills. We are proud to partner with Project Onramp and do our part to foster a rich and inclusive talent pipeline into the biotech industry.? ? Remarking on the event, Vividion CEO Aleksandra Rizo said, “Life Science Cares is an incredibly valued partner to us, and programs like Project Onramp are a testament to the organization’s commitment to helping students in science and biotech gain invaluable professional skills with lasting impact. We’re especially grateful for the San Diego chapter of LSC, which enables us to collectively join together to support the future leaders of our very own community, our home base, that powers Vividion’s mission to transform patient care.”?? ? Thank you to everyone who attended. We are grateful for the opportunity to support the extraordinary talent and passion of the San Diego life science community we call home.? ? #LifeScienceCaresSanDiego #ProjectOnramp #MentorshipMatters #biotech #science?